CorePharm Bio wins patent infringement trial against Astellas
CorePharm Bio won the prohibition trial for patent infringement against Astellas Pharma.
CorePharm Bio(CEO Jung-Tae Kim) announced the 13 Civil Case Division of Seoul Central District Court ruled CorePharm Bio’s A-Care Tab(solifenacin fumarate) does not infringe the substance patent of the Aste...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
